Neuroprotective effects of erythropoiesis-stimulating agents in term and preterm neonates.
Neuroprotective effects of erythropoiesis-stimulating agents in term and preterm neonates.
复制标题
DOI：
10.1097/mop.0000000000000077
复制
发表时间：
2014-04
影响因子：
3.6
通讯作者：
Ohls RK
中科院分区：
文献类型：
--
作者：
Messier AM;Ohls RK
促红细胞生成素(ESA)如促红细胞生成素(EPO)和达贝泊丁(Darbe)在早产儿和足月儿中的应用已有20多年的研究。最近的研究探索了ESA的潜在神经保护作用。我们回顾了最近的临床试验和实验动物模型，这些实验和动物模型提供了支持使用ESA改善足月儿和早产儿神经发育结果的证据。继续使用动物模型的研究证实了ESA的神经保护特性，包括在面临神经元损伤时促进少突胶质细胞的发育。足月儿和早产儿的临床研究报告了ESA给药后的神经保护作用，早产儿的研究报告了神经发育结果的改善。ESA在预防和治疗足月儿和早产儿脑损伤方面显示出巨大的前景。
The use of erythropoiesis stimulating agents (ESAs) such as erythropoietin (Epo) and Darbepoetin (Darbe) in preterm and term infants has been studied for over 20 years. Recent investigations have explored potential neuroprotective effects of ESAs. We review recent clinical trials and experimental animal models that provide evidence in support of using ESA to improve neurodevelopmental outcomes in term and preterm infants. Continued work using animal models have confirmed neuroprotective properties of ESAs, including promotion of oligodendrocyte development in the face of neuronal injury. Clinical studies in term and preterm infants have reported neuroprotective effects following ESA administration, and improved neurodevelopmental outcomes have been reported in studies of preterm infants. ESAs show great promise in preventing and treating brain injury in term and preterm infants.